Coronary heart disease
Conditions
Interventions
Group1:aspirin 100mg qd
Group 2:Xuesaitong 200mg tid
Group 3:aspirin 100mg qd+Xuesaitong200mg tid
Sponsors
Beijing University of Chinese Medicine, Dongzhimen hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 45 to 75 years; 2. meet the diagnostic criteria of CHD; 3. meet the diagnostic criteria of grade I–II angina according to the Canadian Cardiovascular Society (CCS); 4. meet the diagnostic criteria of blood stasis; 5. meet the diagnostic criteria of stable angina pectoris; 6. take regular aspirin for at least one month; 7. be informed of the study and voluntarily sign an informed consent.
Exclusion criteria
Exclusion criteria: 1. mental or physical disorders; 2. pregnant, breast-feeding, and menstruating women, as well as women planning pregnancy within three months; 3. severe heart disease(acute myocardial infarction or acute myocardial infarction in six months), severe cardiopulmonary dysfunction (e.g. cardiac function II); 4. severe primary diseases, such as liver and renal hematopoietic system damage, liver function (ALT>=2 ULN, AST>=2 ULN, kidney function, Cr> 1.0 ULN), or nervous and mental disorder; 5. poorly controlled hypertension (systolic pressure >160 mmHg; or diastolic pressure>100mmHg); 6. having participated in clinical trials in the last three months; 7. underwent surgery or had hemorrhagic tendency in the last eight weeks; 8. drug allergy history or with allergic constitution; 9. diabetes; 10. poor compliance or unsuitability for this clinical trial by investigators judgment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| occult fecal blood;calprotectin;platelet aggregation rate;PAC-1;P selectin; | — |
Secondary
| Measure | Time frame |
|---|---|
| I-FABP;P2Y12; | — |
Countries
China
Contacts
Public ContactBaochen Zhu
Beijing University of Chinese Medicine, Dongzhimen Hospital
Outcome results
None listed